IMARC Group, a leading market research company, has recently released a report titled “Europe Generic Drug Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028.” The study provides a detailed analysis of the industry, including the Europe generic drug market share, size, trends, and growth forecasts. The report also includes competitor and regional analysis and highlights the latest advancements in the market.
How Big is the Europe Generic Drug Market?
The Europe generic drug market size reached US$ 56.7 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 89.1 Billion by 2028, exhibiting a growth rate (CAGR) of 7.6% during 2023-2028.
Factors Affecting the Growth of the Europe Generic Drug Industry:
- Regulatory Environment and Patent Expiry:
The regulatory landscape plays a pivotal role in shaping the growth of the Europe Generic Drug market. European regulatory bodies, such as the European Medicines Agency (EMA), have stringent guidelines for the approval of generic drugs, ensuring their safety and efficacy. Furthermore, the expiration of patents for branded drugs creates opportunities for generic manufacturers. As patents expire, generic drug companies can enter the market, offering more affordable alternatives to consumers. The streamlined approval process for generic drugs post-patent expiry fosters competition and contributes significantly to market expansion.
- Cost Containment and Healthcare Policies:
The European governments are continuously striving to contain healthcare costs while maintaining the quality of medical care. In addition to this, generic drugs are viewed as a cost-effective solution to this challenge. Moreover, national healthcare systems and insurance providers often incentivize the use of generic medications through policies and reimbursements, thus driving the demand for generic drugs. Besides this, government initiatives and policies aimed at encouraging the prescription and consumption of generic drugs are key factors influencing the market growth.
- Increasing Chronic Disease Burden:
The rising prevalence of chronic diseases across Europe, such as cardiovascular diseases, diabetes, and cancer, necessitates a sustainable and cost-efficient healthcare system. Generic drugs are a critical component in managing chronic conditions, as they offer affordable treatment options. The demand for generic drugs is directly linked to the growing burden of chronic diseases, as they provide accessible and economically viable treatment solutions. This trend is expected to continue driving the growth of the Europe Generic Drug market in the foreseeable future.
Request For a PDF Sample Report: https://www.imarcgroup.com/europe-generic-drug-market/requestsample
Europe Generic Drug Market Report Segmentation:
The report is organized into distinct sections as follows:
Breakup by Segment:
- Unbranded Generics
- Branded Generics
By segment, the market is categorised into unbranded generics and branded generics.
Breakup by Therapy Area:
- Central Nervous System
- Cardiovascular
- Dermatology
- Genitourinary/Hormonal
- Respiratory
- Rheumatology
- Diabetes
- Oncology
- Others
By therapy area, central nervous system represented the largest segment because of high prevalence and increasing demand for treatments related to mental health and neurological disorders in Europe.
Breakup by Drug Delivery:
- Oral
- Injectables
- Dermal/Topical
- Inhalers
By drug delivery, oral represented the largest segment due to its ease of administration, patient compliance, and widespread applicability across various drug types.
Breakup by Distribution Channel:
- Retail
- Hospital
By distribution channel, retail pharmacies represented the largest segment as they offer accessibility, convenience, and a broad range of generic drugs to the general public.
Breakup by Country:
- Germany
- France
- United Kingdom
- Italy
- Spain
- Others
Country wise, the market is segmented into Germany, France, the United Kingdom, Italy, Spain, and others.
Europe Generic Drug Market Trends:
The expiration of patents for several blockbuster drugs has opened the market to generic alternatives, leading to increased availability and competition. Moreover, there's a growing emphasis on cost containment in healthcare across Europe. Generic drugs offer a cost-effective alternative to branded medications, significantly reducing healthcare expenditure for both governments and patients.
Additionally, the aging population in Europe contributes to higher demand for medications, including generics. This demographic trend, coupled with the prevalence of chronic diseases, necessitates affordable treatment options. Furthermore, regulatory support from European authorities, encouraging the use of generic drugs through streamlined approval processes and incentives, also plays a crucial role in market growth.
Ask Analyst for Customization and Explore full report with TOC & List of Figures: https://www.imarcgroup.com/request?type=report&id=3276&flag=C
Other Key Points Covered in the Report:
- COVID-19 Impact
- Porters Five Forces Analysis
- Value Chain Analysis
- Strategic Recommendations
If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.
About Us:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact US:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145 | United Kingdom: +44-753-713-2163